The race to supply obesity drugs is so competitive that one startup is already striking a deal for commercial manufacturing even when its lead candidate is still in early stage testing.
Metsera, a biotech focused on obesity drugs that came out of stealth this year, said Tuesday that it is partnering with drug manufacturer Amneal Pharmaceuticals to produce injectable and oral obesity treatments for clinical trials and commercialization.
Under the deal, Amneal will be Metsera’s preferred supplier in developed markets like the U.S. and Europe, and Amneal will be granted a license to sell Metsera’s drugs in certain emerging markets, including India and some countries in Southeast Asia, Africa, and the Middle East. The companies did not disclose the financial terms of the deal.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in